Log in
NASDAQ:INCY

Incyte Competitors

$81.39
-0.54 (-0.66 %)
(As of 11/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$81.33
Now: $81.39
$83.40
50-Day Range
$81.28
MA: $87.56
$97.70
52-Week Range
$62.48
Now: $81.39
$110.36
Volume1.05 million shs
Average Volume1.56 million shs
Market Capitalization$17.82 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.08

Competitors

Incyte (NASDAQ:INCY) Vs. AMGN, GILD, VRTX, REGN, BIIB, and SGEN

Should you be buying INCY stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Incyte, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Seagen (SGEN).

Amgen (NASDAQ:AMGN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Amgen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion5.54$7.84 billion$14.8214.99
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Amgen has higher revenue and earnings than Incyte. Amgen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Amgen has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Amgen and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Incyte-8.00%-8.06%-5.94%

Institutional and Insider Ownership

71.7% of Amgen shares are held by institutional investors. Comparatively, 93.4% of Incyte shares are held by institutional investors. 0.4% of Amgen shares are held by company insiders. Comparatively, 16.1% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Incyte, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen1121502.50
Incyte0101302.57

Amgen currently has a consensus price target of $254.08, indicating a potential upside of 14.34%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's stronger consensus rating and higher possible upside, analysts clearly believe Incyte is more favorable than Amgen.

Summary

Amgen beats Incyte on 8 of the 14 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Gilead Sciences and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gilead Sciences$22.45 billion3.34$5.39 billion$6.149.75
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Gilead Sciences has higher revenue and earnings than Incyte. Gilead Sciences is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Gilead Sciences and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gilead Sciences5.48%37.77%12.76%
Incyte-8.00%-8.06%-5.94%

Institutional & Insider Ownership

77.9% of Gilead Sciences shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Gilead Sciences and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gilead Sciences2151002.30
Incyte0101302.57

Gilead Sciences currently has a consensus price target of $76.1538, indicating a potential upside of 27.16%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than Incyte.

Summary

Gilead Sciences beats Incyte on 8 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Vertex Pharmaceuticals and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.61$1.18 billion$4.2950.79
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Vertex Pharmaceuticals has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Vertex Pharmaceuticals and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Incyte-8.00%-8.06%-5.94%

Institutional & Insider Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Vertex Pharmaceuticals and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals082212.77
Incyte0101302.57

Vertex Pharmaceuticals currently has a consensus price target of $290.5862, indicating a potential upside of 33.38%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Vertex Pharmaceuticals is more favorable than Incyte.

Summary

Vertex Pharmaceuticals beats Incyte on 12 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Regeneron Pharmaceuticals and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion7.11$2.12 billion$21.4724.39
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Regeneron Pharmaceuticals has higher revenue and earnings than Incyte. Regeneron Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Regeneron Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Regeneron Pharmaceuticals and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals37.30%26.71%19.39%
Incyte-8.00%-8.06%-5.94%

Institutional & Insider Ownership

85.9% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Regeneron Pharmaceuticals and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals0101312.63
Incyte0101302.57

Regeneron Pharmaceuticals currently has a consensus price target of $628.52, indicating a potential upside of 20.04%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Regeneron Pharmaceuticals.

Summary

Regeneron Pharmaceuticals beats Incyte on 9 of the 14 factors compared between the two stocks.

Biogen (NASDAQ:BIIB) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings and Valuation

This table compares Biogen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$14.38 billion2.60$5.89 billion$33.577.25
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Biogen has higher revenue and earnings than Incyte. Biogen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Biogen has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Profitability

This table compares Biogen and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Biogen35.63%51.00%23.54%
Incyte-8.00%-8.06%-5.94%

Institutional & Insider Ownership

78.9% of Biogen shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 0.5% of Biogen shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Biogen and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Biogen5151302.24
Incyte0101302.57

Biogen currently has a consensus price target of $305.9032, indicating a potential upside of 25.69%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's stronger consensus rating and higher possible upside, analysts plainly believe Incyte is more favorable than Biogen.

Summary

Biogen beats Incyte on 7 of the 13 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Institutional & Insider Ownership

92.0% of Seagen shares are owned by institutional investors. Comparatively, 93.4% of Incyte shares are owned by institutional investors. 31.1% of Seagen shares are owned by company insiders. Comparatively, 16.1% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Seagen and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seagen-25.17%-18.32%-15.49%
Incyte-8.00%-8.06%-5.94%

Earnings and Valuation

This table compares Seagen and Incyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seagen$916.71 million33.06$-158,650,000.00($1.33)-126.37
Incyte$2.16 billion8.26$446.91 million$2.2336.50

Incyte has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seagen and Incyte, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seagen161112.63
Incyte0101302.57

Seagen currently has a consensus price target of $176.75, indicating a potential upside of 5.16%. Incyte has a consensus price target of $102.9474, indicating a potential upside of 26.49%. Given Incyte's higher possible upside, analysts plainly believe Incyte is more favorable than Seagen.

Risk and Volatility

Seagen has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Incyte has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.

Summary

Incyte beats Seagen on 10 of the 15 factors compared between the two stocks.


Incyte Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.5$222.22-0.4%$129.37 billion$23.36 billion17.92
Gilead Sciences logo
GILD
Gilead Sciences
2.9$59.89-0.4%$75.07 billion$22.45 billion61.74
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.4$217.87-1.2%$56.65 billion$4.16 billion27.51
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.1$523.61-0.9%$55.87 billion$7.86 billion20.27Heavy News Reporting
Biogen logo
BIIB
Biogen
2.0$243.38-0.3%$37.45 billion$14.38 billion8.06
Seagen logo
SGEN
Seagen
1.4$168.07-3.2%$30.30 billion$916.71 million-111.30Insider Selling
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
2.1$122.61-1.0%$26.83 billion$4.99 billion28.65Decrease in Short Interest
Immunomedics logo
IMMU
Immunomedics
1.4$87.86-0.0%$20.31 billion$290,000.00-50.79
Exact Sciences logo
EXAS
Exact Sciences
1.6$120.54-4.4%$18.13 billion$876.29 million-54.54
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$123.02-1.4%$14.29 billion$219.75 million-15.71
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.0$77.04-1.4%$13.99 billion$1.70 billion17.63
Repligen logo
RGEN
Repligen
1.4$185.87-4.1%$9.78 billion$270.24 million320.47Insider Selling
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$93.62-4.9%$8.75 billion$788.10 million44.37
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.8$50.27-2.2%$7.03 billion$1.12 billion104.73
United Therapeutics logo
UTHR
United Therapeutics
1.4$137.77-1.3%$6.12 billion$1.45 billion14.14
Novavax logo
NVAX
Novavax
1.8$93.98-7.9%$5.98 billion$18.66 million-34.17
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.2$22.39-1.8%$5.83 billion$182.24 million-19.47
Exelixis logo
EXEL
Exelixis
1.9$18.39-2.8%$5.71 billion$967.78 million38.31
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$40.02-1.4%$5.41 billion$195.99 million250.13Analyst Report
Heavy News Reporting
Emergent BioSolutions logo
EBS
Emergent BioSolutions
1.8$79.67-3.8%$4.22 billion$1.11 billion25.62Heavy News Reporting
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$57.28-2.1%$3.96 billion$36.13 million-85.49
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.68-0.2%$3.76 billion$806.43 million-9.16
Alkermes logo
ALKS
Alkermes
1.3$18.23-0.1%$2.90 billion$1.17 billion-39.63
OPKO Health logo
OPK
OPKO Health
1.9$3.99-1.3%$2.67 billion$901.90 million-12.09
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.3$11.99-1.8%$1.92 billion$428.41 million17.38
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.9$113.04-1.6%$1.75 billionN/A-10.21Analyst Report
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.5$9.99-2.6%$1.41 billion$102.43 million-12.04
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$86.25-3.5%$1.39 billion$120.28 million-87.12
Myriad Genetics logo
MYGN
Myriad Genetics
1.3$17.69-2.7%$1.33 billion$638.60 million-6.60
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$35.47-0.5%$1.17 billion$252 million-3.42Analyst Revision
Innoviva logo
INVA
Innoviva
1.1$10.69-2.4%$1.08 billion$261.02 million5.45
ImmunoGen logo
IMGN
ImmunoGen
1.7$5.68-5.5%$1.07 billion$82.27 million-13.21Increase in Short Interest
Codexis logo
CDXS
Codexis
1.1$17.38-0.2%$1.03 billion$68.46 million-49.66
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.4$21.25-6.3%$840.80 million$3.57 million-9.53
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.6$4.40-1.6%$776.89 million$48.83 million-5.79Analyst Report
MannKind logo
MNKD
MannKind
0.9$3.06-5.2%$711.76 million$63.04 million-14.57
Agenus logo
AGEN
Agenus
1.6$3.58-2.0%$680.73 million$150.05 million-3.28
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.4$12.22-1.1%$668.34 million$227.19 million5.85
BioSpecifics Technologies logo
BSTC
BioSpecifics Technologies
1.3$88.44-0.0%$649.59 million$38.19 million37.47
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$4.36-0.9%$636.22 million$109.33 million-3.57Increase in Short Interest
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$2.78-1.8%$595.73 million$150,000.00-3.97
Geron logo
GERN
Geron
1.4$1.86-1.1%$577.48 million$460,000.00-5.31
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$2.86-3.8%$483.29 million$59.29 million-20.43Increase in Short Interest
AMAG Pharmaceuticals logo
AMAG
AMAG Pharmaceuticals
0.8$13.75-0.0%$477.47 million$327.75 million-1.89
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$4.20-5.2%$462.73 million$35.22 million-3.07
Molecular Templates logo
MTEM
Molecular Templates
1.6$9.00-0.0%$449.68 million$22.27 million-4.41Increase in Short Interest
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$4.18-1.2%$369.17 million$143.01 million-0.80
XOMA logo
XOMA
XOMA
1.4$33.03-1.1%$364.06 million$18.37 million-29.76
PDL BioPharma logo
PDLI
PDL BioPharma
1.3$2.47-0.8%$282.14 million$54.76 million-1.86
Verastem logo
VSTM
Verastem
1.5$1.47-0.7%$249.57 million$17.46 million-1.04
This page was last updated on 11/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.